BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35677634)

  • 1. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
    Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
    Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
    Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
    J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma.
    Ji J; Liu S; Liang Y; Zheng G
    BMC Genom Data; 2023 Aug; 24(1):44. PubMed ID: 37568073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas.
    Sun C; Zheng X; Sun Y; Yu J; Sheng M; Yan S; Zhu Q; Lan Q
    Front Genet; 2021; 12():743738. PubMed ID: 34721530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of
    Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
    DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.
    Chen S; Li X; Guo L; Zhang J; Li L; Wang X; Zhu Y; Wang J
    J BUON; 2021; 26(5):1931-1941. PubMed ID: 34761602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of m
    Liu T; Li H; Du G; Ma J; Shen J; Zhao H; Luo F; Li H
    Gene; 2022 May; 821():146250. PubMed ID: 35151825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting IGF2BP3 in Cancer.
    Liu X; Chen J; Chen W; Xu Y; Shen Y; Xu X
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
    Fan J; Zhuang M; Fan W; Hou M
    PeerJ; 2023; 11():e15706. PubMed ID: 37663284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of m
    Kuai D; Zhu S; Shi H; Yang R; Liu T; Liu H; Min L; Zhang S
    Life Sci; 2021 May; 273():119258. PubMed ID: 33636176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF2BP3 is an essential N
    Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
    Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
    Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
    Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
    [No Abstract]   [Full Text] [Related]  

  • 17. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
    Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients.
    Zhang P; Liu G; Lu L
    Front Cell Dev Biol; 2021; 9():703629. PubMed ID: 34336856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
    Xu D; Shao J; Song H; Wang J
    Biomed Res Int; 2020; 2020():9502560. PubMed ID: 32596399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.